Early stage mucinous ovarian carcinomas: 10 years of experience in a tertiary centre
Chatterjee J. et al, (2013), BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 120, 282 - 283
Management of ascites via the alfa-pump closed system in platinum-resistant-ovarian-cancer (PROC): A model of sequential non-invasive tumor-cell sampling through the urinary bladder
Fotopoulou C. et al, (2013), CLINICAL CANCER RESEARCH, 19
OUTCOMES IN MUCINOUS OVARIAN CARCINOMAS: 10 YEARS OF EXPERIENCE IN A TERTIARY CENTRE
Hopkins TG. et al, (2013), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 23
THE IMPACT OF OVARIAN CANCER TREATMENT ON WOMEN'S SEXUAL WELLBEING
Hopkins TG. et al, (2013), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 23
Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.
Harding V. et al, (2012), Br J Cancer, 107, 925 - 930
A study of symptoms described by ovarian cancer survivors.
Stavraka C. et al, (2012), Gynecol Oncol, 125, 59 - 64
Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer.
Li HK. et al, (2012), J Clin Oncol, 30, e19 - e20
Epithelial Ovarian Cancer
Gabra H. and Blagden S., (2012), Dewhurst's Textbook of Obstetrics & Gynaecology: Eighth Edition, 760 - 775
LARP1 Regulates the Site-specific Synthesis of Proteins Required for Cancer Cell Invasion and Migration
Mura M. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, S77 - S77
Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma
Soria JC. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 188 - 188
MNK 1 and 2 Inhibitors Are Active in Platinum-resistant Ovarian Cancer Cells
Mura M. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 26 - 26
Multivariate screening of prognostic factors to identify a novel, simple, and objective marker to optimize patient selection and predict survival benefit in early-phase trials.
Stavraka C. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors
Gan H. et al, (2012), EUROPEAN JOURNAL OF CANCER, 48, 189 - 189
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.
Coley HM. et al, (2012), Oncotarget, 3, 78 - 83
Use of inflammation-based scores to optimize the selection of patients with advanced cancer considered for early-phase clinical trials
Pinato DJ. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ. et al, (2011), N Engl J Med, 365, 2484 - 2496
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D. et al, (2011), Clin Cancer Res, 17, 3420 - 3430
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Syed N. et al, (2011), Cancer Res, 71, 3317 - 3327
The biological and therapeutic relevance of mRNA translation in cancer.
Blagden SP. and Willis AE., (2011), Nat Rev Clin Oncol, 8, 280 - 291